Zonisamide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), HAS (France) and SMC (Scotland), among others, recommended or restricted zonisamide, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 17.4 years separate the first record, 16 Nov 2005 at HAS (France), from the most recent, 19 Apr 2023 at HAS (France).
No assessment is on file from PBAC (Australia), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for zonisamide, 1 submission was never made — an outcome set by the company rather than the assessor.
4 distinct indication wordings are recorded for zonisamide by the agencies that label one in English (AWMSG and SMC).
HAS (France) was first to assess zonisamide, on 16 Nov 2005; PHARMAC (New Zealand) did not open a file until 11 Feb 2022 — an unusually long tail of 16.2 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 2 of 7 decisive outcomes narrowed zonisamide to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland) and SMC (Scotland).
4 of the 6 agencies here assessed zonisamide more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for zonisamide.
The full ledger for zonisamide reads 6 other, 3 recommended, 2 restricted and 2 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 19 Apr 2023 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PHARMAC (New Zealand) | 11 Feb 2022 | Monotherapy treatment for refractory partial epilepsy | PTAC advice: No Formal Recommendation | source |
| AOTMIT (Poland) | 30 Jan 2018 | Zonegran reimbursement recommendation | recommended conditionally | source |
| AWMSG (Wales) | 27 Feb 2014 | For use as adjunctive therapy in the treatment of partial seizures with or without secondary generalisation in adolescen… | not endorsed (non-submission) | source |
| SMC (Scotland) | 8 Oct 2012 | monotherapy for the treatment of partial seizures (with or without secondary generalization) in adults with newly diagnosed epilepsy. | not recommended | source |
9 further decisions for zonisamide, across 5 agencies, are not shown here. They link to 6 further source documents.
Related molecules
- eslicarbazepine — divergent outcome (other vs recommended) on a shared indication
- cannabidiol — same ATC class N03A — Antiepileptics
- levetiracetam — same ATC class N03A — Antiepileptics
- perampanel — same ATC class N03A — Antiepileptics
- lacosamide — same ATC class N03A — Antiepileptics
- brivaracetam — same ATC class N03A — Antiepileptics
Coverage: 14 decisions for zonisamide from 6 agencies, 2005 to 2023. Data to 7 Sep 2026. ATC class N03A — Antiepileptics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.